Principal Scientist Janssen Research & Development, LLC Spring House
CAR-T cell therapy has shown promising clinical responses in the treatment of cancer. The engineered T cell carries a chimeric antigen receptor (CAR) that redirects killing activity against tumor cells expressing the CAR target. However, the CAR structure may trigger the generation of anti-CAR antibodies (ADA) in patients. This immune response could lead to the clearance of CAR-T cells and a subsequent reduction in the effectiveness of CAR-T therapy. In this study, we have compared the MSD based bridging assay and flow cytometry assay formats for the assessment of ADA response to autologous CAR-T therapy. The bridging assay format was selected for the autologous CAR-T ADA assessment.
Learning Objectives:
Upon completion, the participants will be able to understand the Anti-Drug Antibody assay for CAR-T cell therapy.
